Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $17.56, for a total value of $210,720.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Samuel Kintz also recently made the following trade(s):

• On Thursday, January 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.69, for a total value of $188,280.00.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $18.63 on Thursday. The stock’s 50 day moving average is $15.83 and its 200 day moving average is $13.84. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $24.22.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ELVN. Barclays PLC purchased a new stake in shares of Enliven Therapeutics in the 1st quarter worth approximately $158,000. Bank of New York Mellon Corp purchased a new stake in Enliven Therapeutics during the 1st quarter valued at $335,000. Tower Research Capital LLC TRC purchased a new stake in Enliven Therapeutics during the 1st quarter valued at $36,000. Citigroup Inc. purchased a new stake in Enliven Therapeutics during the 1st quarter valued at $247,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Enliven Therapeutics during the 1st quarter valued at $217,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.